Saturday, October 31, 2026

Canaan Stock Soars 19%: Investors Bet On Blockchain Boom

ViaNews Editorial Team

December 23, 2023

Canaan Stock Soars 19%: Investors Bet On Blockchain Boom

(VIANEWS) - Canaan Inc. (NASDAQ: CAN) shares rose an extraordinary 19.96% to EUR3.10 at 21:34 EST on Friday, extending gains for six sessions in a row and helping propel NASDAQ's performance with an uptick of 0.28%, reaching EUR15,005.87; Canaan closed at a price of EUR2.58 which was 35.18% below its 52-week high of EUR3.998.

About Canaan

Canaan Inc. was established in Singapore in 2013 and specializes in research, design and sale of final IC mining equipment products for bitcoin mining. Canaan also integrates related components in China and is involved with assembly distribution sale of mining equipment and spare parts globally - operating globally across US Australia Kazakhstan Hong Kong Canada Mainland China Thailand Sweden as well as internationally.

Yearly Analysis

Canaan's stock is currently trading at EUR3.10, significantly below its 52-week high of EUR3.98 but above its 52-week low of EUR1.44. This suggests that Canaan may have oversold itself and could provide investors with an excellent investment opportunity at lower prices. However, Canaan's sales growth is expected to decline significantly this year and next, reaching negative 69% - an alarming sign. Even though sales growth should rebound to 12.5% next year, investors should remain mindful of how a pandemic could disrupt business operations. Furthermore, Canaan has an EBITDA ratio of 0.53 which indicates positive cash flow - another good sign. Canaan stock may appear oversold and represent an investment opportunity. But before making any definitive decisions regarding their purchase or sell decision, investors should carefully consider its negative sales growth and impact of pandemic on company operations before making their investment decision. It may be prudent to conduct further research into Canaan's financial performance, management team composition and industry trends before reaching any definitive verdict on it.

Technical Analysis

Canaan Inc. (NASDAQ: CAN) has seen its stock prices surge recently, reaching EUR4.78 - significantly above both its 50-day moving average of EUR1.78 and 200-day moving average of EUR2.31. This sudden uptick may be linked to positive news related to operations and financial performance at Canaan Inc. Canaan's trading volume has also seen an upward trend since its stock price increase; today's reported volume stands at 267,772,970 -- 310.38% above its usual monthly volume of 6,524,860 -- which suggests that more investors have taken an interest in its shares. Canaan saw intraday variation averages of 10.40% over the past week, month, and quarter with maximum amplitudes reaching 10.42% (week), 8.144% (month), and 5.10% (quarter). According to the stochastic oscillator, an effective indicator for measuring overbought and oversold conditions, Canaan's stock appears to be oversold (=20). This suggests that its value may have been underappreciated and could potentially rise in coming days. Overall, Canaan's stock price increase, higher-than-average trading volume and oversold status according to the stochastic oscillator indicate that it may represent an attractive investment opportunity at lower price points for investors looking for entry point investments. It is recommended to conduct their own due diligence prior to making any definitive investments decisions.

Quarter Analysis

Canaan's financial performance is clearly declining. Negative sales growth for the current and next quarters suggests an erosion in revenue growth over the last twelve months (75.1% decrease YoY). Growth estimates for both current and upcoming quarters at 34.6% and 75% indicate some optimism for future expansion, though these projections can change without notice due to negative sales growth and declining revenue - both factors which could impede on achieving those estimates. Canaan's investment outlook is uncertain and requires caution when investing in the company, with both positive and negative indicators showing up as indicators for investors to make informed investment decisions.

Equity Analysis

Canaan has reported its trailing twelve month earnings per share as EUR-0.47, signifying negative profits for shareholders. This indicates the company is currently failing to generate profits for them. Return on Equity (ROE) for the twelve trailing months was negative -53.23%, which indicates that shareholders' equity is not being effectively utilized to generate profits for them. Overall, Canaan's financial indicators suggest it may be facing challenges in terms of profitability and shareholder value, so investors may wish to carefully consider this information prior to making any investment decisions.

More news about Canaan (CAN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com